Evidence map›Paper›PMID 40859871›Full record

ReviewJournal of cellular and molecular medicine2025

Synthetic Lethality-Based Targets and Their Exploration in Tumour Combination Strategies.

Lingya Wu, Yixuan Deng, Zhe Lei, Yuhong Wang, Shan Huang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lingya WuDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.ORCID 0009-0001-7496-7308
Yixuan DengDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Zhe LeiDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Yuhong WangDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Shan HuangDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

Funding

Basic science (Natural science) research project in universities of Jiangsu Province 24KJB310015National Natural Science Foundation of China 82473045Suzhou Basic Research Pilot Program SSD2024040Suzhou "Gusu Medical Star" Young Science and Technology Talent Support Project GSYX(2024)38Suzhou health youth backbone talent 'national tutorial system' training project Qngg2023005Suzhou Science and Technology Bureau basic research special youth project SSD2024073
6 · The paper itself

Abstract

Synthetic lethality (SL) not only addresses the challenge of drug resistance associated with classical targeted therapies but also offers innovative therapeutic approaches for previously 'undruggable' targets, such as deletion mutations in tumour suppressor genes. Advances in technology have significantly enhanced our understanding of gene-gene interactions in cancer cells, enabling the identification of synthetic lethal targets and the development of drugs targeting these mechanisms. Following the extensive clinical application of PARP inhibitors-the first synthetic lethal targeted drugs approved for clinical use-emerging targets such as ATR, WEE1 and WRN have demonstrated promising clinical potential. This review examines the functions and molecular mechanisms underlying these targets and discusses recent advancements in the theory of synthetic lethality. Additionally, it emphasises the integration of synthetic lethal drugs with traditional cancer treatments, highlighting the clinical benefits of this combined strategy and its potential to facilitate more precise and individualised cancer treatment modalities in the future.

Indexed as

Molecular Targeted TherapyNeoplasmsSynthetic Lethal MutationsAnimalsAntineoplastic AgentsHumansPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsPoly(ADP-ribose) Polymerase Inhibitorscancer therapycombined strategyDNA repairPARP inhibitorssynthetic lethality

Identifiers

PMID40859871
PMCPMC12381573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.